安徽广信农化股份有限公司 舆情管理制度 安徽广信农化股份有限公司 舆情管理制度 （经 2024 年 12 月公司董事会审议通过） 第一章 总则 第一条 为提高安徽广信农化股份有限公司（以下简称"公司"）应对各类舆情 的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股价、公 司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益，根据相关 法律、法规和规范性文件的规定及《安徽广信农化股份有限公司章程》（以下简称 《公司章程》），结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大 影响的事件信息。 第三条 公司舆情管理应坚持"科学应对、突出导向、注重实效"的总体原则， 有效引导内部舆论和社会舆论，避免和消除因媒体可能对公司造成的各种负面影响， 切实维护公司的利益和形象。 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类 ...

证券代码：603599 证券简称：广信股份 公告编号：2024-042 安徽广信农化股份有限公司 关于变更签字注册会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 安徽广信农化股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 公司第五届董事会第十九次会议及 2024 年 6 月 7 日召开 2023 年年度股东大会， 审议通过了《关于续聘会计师事务所的议案》，同意续聘容诚会计师事务所(特殊 普通合伙)（以下简称"容诚"）为公司 2024 年度财务报表审计和内部控制审计 的会计师事务所。具体内容详见公司于 2024 年 4 月 26 日在上海证券交易所网站 （http://www.sse.com.cn）披露的《关于续聘会计师事务所的公告》（公告编号： 2024-012）。 近日，公司收到容诚送达的《关于变更签字注册会计师的函》，现将相关变 更情况公告如下： 一、本次签字会计师变更的基本情况 容诚作为公司 2024 年度审计机构，原委派鲍灵姬、孙青、杨卓凡作为签字 注册会计师为公司提供 20 ...

证券代码：603599 证券简称：广信股份 公告编号：2024-041 安徽广信农化股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 安徽广信农化股份有限公司（以下简称"公司"）已于 2024 年 10 月 29 日发 布公司 2024 年三季度报告，为便于广大投资者更全面深入地了解公司 2024 年三 季度经营成果、财务状况，公司计划于 2024 年 12 月 02 日 下午 16:00-17:00 举行 2024 年三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2024 年 12 月 02 日(星期一) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://r ...

Investment Rating - The report maintains an "Outperform" rating for the company [5][6][10] Core Views - The company reported stable overall operations in Q3 2024, with performance in line with expectations, while awaiting a recovery in industry conditions [5] - Q3 2024 revenue reached 3.49 billion yuan, a year-on-year decrease of 31%, with a net profit attributable to shareholders of 574 million yuan, down 57% year-on-year [5][6] - The company is focusing on enhancing its industrial chain layout, with new projects expected to contribute to performance growth [5] Financial Summary - Q3 2024 revenue was 1.20 billion yuan, a year-on-year decrease of 9% but a quarter-on-quarter increase of 12% [5] - The gross margin for Q3 2024 was 30.66%, with a net margin of 13.47% [5] - The company’s main pesticide raw material sales volume was 23,400 tons, up 34% year-on-year, generating revenue of 668 million yuan [5] - The average selling price of key pesticide raw materials showed a year-on-year decline, with glyphosate at 25,100 yuan/ton, down 23% [5] Future Projections - The company’s projected net profits for 2024-2026 are revised to 746 million, 944 million, and 1.20 billion yuan respectively, reflecting a downward adjustment due to expected low industry demand [5][6] - The projected PE ratios for 2024-2026 are 14, 11, and 8 times, respectively, compared to an industry average of 20 times [5][6]

证 券 研 究 报 告 广信股份（603599）2024 年三季报点评 强推（维持） 业绩底部震荡，期待新品释放 目标价：14.52 元 当前价：10.89 元 事项： 广信股份发布 2024 年三季度报告，24Q1-Q3 实现营收 34.90 亿元，同比31.46%，实现归母净利润 5.74 亿元，同比-56.61%。其中 Q3 实现营收 12.03 亿 元，同 / 环比-8.83% / +12.23%，实现归母净利润 1.62 亿元，同 / 环比-46.09% / -13.37%。 评论： 财务方面：毛利率环比提升，财务费用影响净利率。24Q3，公司实现毛利率 30.66%，环比+0.35PCT，实现净利率 13.47%，环比-3.98PCT，毛利提升、净 利下滑的原因主要来自于财务费用的环比上行。24Q3 公司财务费用为 0.02 亿 元，环比+0.97 亿元，财务费用率为 0.14%，环比+9.01 PCT，财务费用的上行 可能来自于 1）利息收入有所降低，24H1 公司利息收入为 1.18 亿元，24Q3 公 司利息收入仅为 0.46 亿元，较上半年均值明显下滑；2）汇兑损失拖累，财务 费用中除利息 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing short-term performance pressure with a significant decline in revenue and profit, but it continues to improve its long-term industrial chain layout [1] - The company reported a total revenue of 3.49 billion yuan for the first three quarters of 2024, a year-on-year decrease of 31.46%, and a net profit attributable to shareholders of 574 million yuan, down 56.61% year-on-year [1] - The average selling price of key pesticide products has dropped significantly, impacting the company's Q3 performance [1] - The company has established a complete industrial chain from fine chemicals to pesticides and pharmaceutical intermediates, which is expected to enhance its competitive edge [1] - The company is accelerating its layout in pharmaceutical intermediates and new materials, which are expected to improve overall profitability [2] Summary by Relevant Sections Financial Performance - In Q3 2024, the company achieved total revenue of 1.20 billion yuan, a year-on-year decrease of 8.83% but a quarter-on-quarter increase of 12.23% [1] - The net profit attributable to shareholders for Q3 2024 was 162 million yuan, down 46.09% year-on-year and down 13.37% quarter-on-quarter [1] - The company expects net profits for 2024-2026 to be 803 million yuan, 1.05 billion yuan, and 1.40 billion yuan respectively, with corresponding P/E ratios of 12X, 9X, and 7X [2] Market Conditions - The pesticide market is currently experiencing low demand, leading to a downward adjustment in profit expectations for the company [2] - The average selling price of glyphosate has decreased by 50% year-on-year, significantly affecting revenue [1] Strategic Initiatives - The company has a production capacity of 320,000 tons/year of phosgene, leading the private sector in pesticide production [1] - Future plans include further refining the industrial chain to enhance cost efficiency and product quality [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第十八号—化工》、《关 于做好上市公司 2024 年第三季度报告披露工作的通知》的要求，安徽广信农化 股份有限公司（以下简称"公司"）现将 2024 年第三季度主要经营数据披露如 下： 一、 主要产品的产量、销量及收入实现情况 | 项目 | 2024 年 | | 7-9 | 月产 | 2024 | 年 | 7-9 | 月销量 2024 | | 年 | 7-9 | 月销售 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 量（吨） | | | （吨） | | | | 金额（万元） | | | | | 主要农药原药 | | | | 20,784.40 | | | | 23,387.96 | 66,849.42 | | | | | 主要农药中间体 | | | 170,566.27 | | 182,276.55 | ...

Financial Performance - Revenue for Q3 2024 was CNY 1,202,535,224.96, a decrease of 8.83% year-over-year, and year-to-date revenue decreased by 31.46% to CNY 3,489,513,084.25[2] - Net profit attributable to shareholders for Q3 2024 was CNY 162,008,917.02, down 46.09% year-over-year, with a year-to-date decrease of 56.61% to CNY 574,181,253.05[2] - Basic earnings per share for Q3 2024 was CNY 0.18, a decline of 45.45%, and year-to-date basic earnings per share decreased by 56.55% to CNY 0.63[4] - Total operating revenue for the first three quarters of 2024 was CNY 3,489,513,084.25, a decrease of 31.5% compared to CNY 5,090,960,006.79 in the same period of 2023[16] - Net profit for the first three quarters of 2024 was CNY 569,565,538.29, a significant decline of 57.5% from CNY 1,338,489,668.20 in the same period of 2023[19] - Earnings per share for the first three quarters of 2024 was CNY 0.63, compared to CNY 1.45 in the same period of 2023, indicating a decrease of 56.6%[19] Cash Flow and Liquidity - Cash flow from operating activities year-to-date was CNY 520,822,253.65, a decrease of 57.48% compared to the previous year[2] - In the first three quarters of 2024, the company's cash inflow from operating activities was approximately CNY 2.49 billion, a decrease of 38.3% compared to CNY 4.05 billion in the same period of 2023[20] - The net cash outflow from investing activities was CNY 290.82 million, significantly down from CNY 1.47 billion in the previous year, indicating a reduction in investment expenditures[21] - The company reported a net cash inflow from financing activities of CNY 1.07 billion, an increase from CNY 260.68 million in the same period last year, reflecting improved financing conditions[21] - The total cash and cash equivalents at the end of the period reached CNY 7.57 billion, up from CNY 5.90 billion at the end of the same period last year, showing a strong liquidity position[21] - The net increase in cash and cash equivalents for the period was CNY 1.87 billion, down from CNY 3.01 billion in the previous year, reflecting a tighter cash flow situation[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 15,524,392,896.11, reflecting a slight increase of 0.05% from the end of the previous year[4] - The company's total liabilities as of the end of the third quarter of 2024 were CNY 6,036,760,198.40, an increase from CNY 5,902,309,187.56 at the end of the same period in 2023[18] - Shareholder equity attributable to shareholders was CNY 9,487,632,697.71, a decrease of 1.33% from the end of the previous year[4] - The total equity attributable to shareholders of the parent company was CNY 9,487,632,697.71, slightly up from CNY 9,483,719,229.35 in the previous year[18] Operational Metrics - The company experienced a significant decline in sales volume and product prices, impacting overall profitability[7] - Total operating costs for the first three quarters of 2024 were CNY 2,867,446,769.41, down from CNY 3,703,172,629.23 in 2023, reflecting a reduction of 22.6%[18] - The cash received from sales of goods and services was CNY 2.22 billion, down 43.5% from CNY 3.93 billion in the previous year, indicating a decline in sales performance[20] - The cash outflow for purchasing goods and services was CNY 1.20 billion, down 28.2% from CNY 1.67 billion in the previous year, indicating cost control measures[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,018[9] - The top shareholder, Anhui Guangxin Group Co., Ltd., holds approximately 351.18 million shares, representing a significant portion of the company's equity[11] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[11] Research and Development - Research and development expenses for the first three quarters of 2024 were CNY 215,207,999.75, down from CNY 238,336,655.12 in 2023, a decrease of 9.7%[18] - The company has not disclosed any significant new strategies or product developments during the reporting period[12] Other Financial Metrics - Non-recurring gains and losses for Q3 2024 included government subsidies of CNY 120,663.49, while total non-recurring losses year-to-date amounted to CNY -100,823,390.33[5] - The weighted average return on equity for Q3 2024 was 1.63%, a decrease of 1.69 percentage points year-over-year, and year-to-date it was 5.96%, down 8.33 percentage points[4] - The company reported a financial income of CNY 164,045,888.71 in the first three quarters of 2024, compared to CNY 65,944,493.40 in the same period of 2023, showing an increase of 148.5%[18] - Deferred income tax liabilities increased to CNY 48,892,910.84 from CNY 39,282,179.78 year-over-year, reflecting a rise of 24.1%[18]

Investment Rating - The report assigns a "Strong Buy" rating to the company, with a target price of 15.84 CNY based on a 2024 PE of 18 times [1][7]. Core Insights - The company has established a dual industrial chain layout, enhancing profitability and opening up multiple avenues for growth. It has a significant cash reserve of 8.231 billion CNY, which supports its long-term growth potential [1][6]. - The company is expected to benefit from the launch of new pesticide products in 2024-2025, which will enrich its product lineup and elevate profit margins [1][6]. - The company has a strong return on equity (ROE) that has increased from 7% in 2015 to 31% in 2020, indicating a robust financial performance that is currently undervalued by the market [1][6]. Summary by Sections Company Overview - Guangxin Co., Ltd. was established in 2000 and has developed a dual industrial chain layout in its production bases located in Guangde and Dongzhi, focusing on phosgene and chlorobenzene [1][14]. - The company holds the largest phosgene production capacity among private enterprises in China, with a licensed capacity of 320,000 tons per year [1][14]. Industrial Chain Layout - The company has completed its industrial chain layout for phosgene and chlorobenzene, which includes upstream, midstream, and downstream operations, providing a competitive edge in cost and production efficiency [1][27]. - The phosgene chain is characterized by its scarcity and regulatory constraints, while the chlorobenzene chain has seen increased competition, which may reshape the market dynamics [1][27]. Financial Performance - The company reported a total revenue of 5.868 billion CNY in 2023, with a projected decline to 5.617 billion CNY in 2024, followed by a recovery to 7.404 billion CNY in 2025 [2]. - The net profit attributable to shareholders is expected to decrease from 1.439 billion CNY in 2023 to 804 million CNY in 2024, before rebounding to 1.259 billion CNY in 2025 [2]. Growth Drivers - The company is set to launch several new pesticide products, including 1,500 tons of isoxaben and 3,000 tons of thiamethoxam, which are anticipated to significantly boost revenue and profit margins [1][6]. - The company has a strong cash position, with net cash totaling 8.231 billion CNY, which will facilitate its entry into new markets and support ongoing capital expenditures [1][6]. Valuation - The report highlights that the company's valuation is currently at the bottom of the industry range, with a PE ratio of around 11 times, which is expected to recover as profits stabilize and new projects come online [1][6]. - The adjusted return on invested capital (ROIC) for 2022 was reported at 47%, significantly higher than industry peers, indicating strong operational efficiency [1][6].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company's performance in H1 2024 showed a significant decline, with revenue of 2.3 billion yuan, down 39% year-on-year, and a net profit attributable to shareholders of 410 million yuan, down 60% year-on-year [2][6] - The decline in performance is primarily attributed to the ongoing downturn in the pesticide industry, with both volume and price decreasing [6] - Despite the current challenges, there are signs of improvement in export demand for pesticides, with a notable increase in export volume and value in Q2 2024 [6] - The company has a strong cash position with 11.4 billion yuan in cash assets and a low debt level, which supports its ongoing projects and future growth [6] Summary by Sections Financial Performance - In H1 2024, the company achieved revenue of 2.3 billion yuan, a decrease of 39% year-on-year, and a net profit of 410 million yuan, down 60% year-on-year [2][6] - For Q2 2024, revenue was 1.1 billion yuan, down 42% year-on-year, and net profit was 190 million yuan, down 63% year-on-year [6] - The sales volume of raw materials and intermediates in Q2 2024 was approximately 180,000 tons and 137,000 tons, down 5% and 19% year-on-year, respectively [6] Market Outlook - The pesticide industry is expected to see a recovery in the medium to long term, driven by resilient end-user demand and reduced inventory levels in global distribution channels [6] - The export of pesticides has shown significant growth, with a 54% increase in export volume and a 30% increase in export value in Q2 2024 [6] Company Position - The company has a robust cash position with 11.4 billion yuan in cash assets and total borrowings of 3.1 billion yuan [6] - The successful launch of new projects, including 300,000 tons of ion membrane caustic soda and 40,000 tons of para-aminophenol, enhances the company's integrated supply chain [6] - The company is expected to continue its growth trajectory with ongoing project developments [6]